Navigation Links
NLST data highlight probability of lung cancer overdiagnosis with low-dose CT screening
Date:12/9/2013

Philadelphia, PAData from the National Lung Cancer Screening Trial (NLST)conducted by the American College of Radiology Imaging Network and National Cancer Institute Lung Screening Studyprovided researchers the opportunity to investigate the probability that a cancer detected with screening low-dose computed tomography (LDCT) would not have progressed to become life threatening. The results of this investigation published online today in JAMA Internal Medicine suggest that up to 18 percent of the cancers detected by LDCT may not have progressed enough to affect patient health if left undetected.

"This is another piece of important information that helps us to better understand the benefits and risks of lung cancer screening," says the study's lead author, Edward F. Patz, Jr., M.D., a professor of radiology, and pharmacology and cancer biology at Duke University School of Medicine.

"The NLST provided encouraging data demonstrating that lung cancer screening with CT reduces death from the disease. However, there are inherent risks with any mass screening program, and this paper investigates the probability of overdiagnosismeaning, if some patients never would have been screened for lung cancer, they would never have known they had the disease because it would never have caused symptom."

The specific negative consequences of overdiagnosis described by the authors include unnecessary invasive diagnostic procedures, treatment, morbidity (and mortality in rare cases), follow-up, cost, patient anxiety, and labeling of patients with a disease that otherwise would never have been detected.

Using NLST data, the authors determined an "upper bound to true overdiagnosis rate" because the post-screening follow-up period in NLST may not have been long enough to totally differentiate overdiagnosis from the effects of lead timethe length of time a diagnosis was moved up due to early detection by screening. The probability that any lung cancer (all types and stages) detected by screening with LDCT is an overdiagnosis was reported as 18.5 percent. The probability that an LDCT-detected non-small cell lung cancerby far the most frequently diagnosed lung cancer typerepresents an overdiagnosis was found to be 22 percent. The overdiagnosis rate for bronchioloalveolar lung cancer was 78.9 percent.

Patz explains that the problem clinicians face is not knowing which patients are among the approximate 18 percent who have indolent disease. "Patients with these nonaggressive cancers are treated the same as any other patient with lung cancer, because it is generally not possible to distinguish indolent lesions from more aggressive tumors," says Patz. The authors emphasize the need for better biomarkers and imaging techniques to determine which lung cancers are more or less aggressive so as to optimize patient care and enhance the value of screening programs.

"Overdiagnosis is something we don't commonly think exists in lung cancer as compared with, for example, prostate cancer," says Patz. "Most often, when patients are diagnosed with lung cancer, it's viewed as a fatal disease. However, these data confirm that's not necessarily the case with screening programs, which is important information for clinicians to discuss with their patients."

"The relatively modest rate of overdiagnosis with low-dose CT compared with the overdiagnosis rate projected for other cancer screenings programs, further supports the implementation of lung cancer screening programs. Of course, it's important that we work to further drive down overdiagnosis rates across all screening programs," says Mitchell D. Schnall, M.D., Ph.D., Co-Chair of the ECOG-ACRIN Cancer Research Group and the Radiology Department Chair at the University of Pennsylvania's Perelman School of Medicine.


'/>"/>

Contact: Shawn Farley
PR@acr.org
703-648-8936
American College of Radiology
Source:Eurekalert

Related biology technology :

1. The Zacks Analyst Blog Highlights: Celgene, Biogen, Gilead, Orexigen and Cubist
2. How to Enhance Scientific Intuition in Pharmaceutical R&D: the CBCD Highlights a Revolutionary New Technology
3. Amgen to Highlight New Evolocumab (AMG 145) Data at Upcoming American Heart Association Scientific Sessions 2013
4. Bend Research to Highlight Latest Drug Formulation Technologies
5. Pittcon 2014 Announces Highlights of Annual Waters Symposium
6. The Zacks Analyst Blog Highlights: Eaton, Baxter International, Bio-Rad Laboratories, INSYS Therapeutics and Boston Scientific
7. SCAI Paper Highlights Best Practices For Diagnosing And Treating Blocked Arteries Via The Wrist
8. Apache's New Video Highlights Benefits of Employee Ownership
9. SACHEM Booth #1441 At SEMICON Europa Oct 8-10th, Highlighting Envure System™
10. The Zacks Analyst Blog Highlights: SPDR Health Care Select Sector Fund, SPDR S&P 500, SPDRS&P Biotech ETF, PowerShares S&P SmallCap Health Care Portfolio and PowerShares Dynamic Biotechnology & Genome Portfolio
11. Cellular Biomedicine Group Reports Second Quarter and First Half 2013 Financial Results and Business Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... 8, 2016 Oxford ... erweitert seine Palette an anpassbaren SureSeq™ NGS-Panels mit ... Panels, das ein schnelles und kostengünstiges Studium der ... bietet eine Erkennung von Einzel-Nukleotid-Variationen (Single Nucleotide Variation, ... einzigen kleinen Panel und ermöglicht eine individuelle Anpassung ...
(Date:12/8/2016)... Frederick, Maryland (PRWEB) , ... ... ... Inc announces the commercial launch of flexible packaging for their exceptionally ... (“SU”) disposable bag system extends RoosterBio’s portfolio of bioprocess media products engineered ...
(Date:12/8/2016)... , Dec. 8, 2016 Soligenix, Inc. ... company focused on developing and commercializing products to treat ... announced today that it will be hosting an Investor ... ET on the origins of innate defense regulators (IDRs) ... review of oral mucositis and the recently announced and ...
(Date:12/8/2016)... to fuel Philadelphia,s innovative digital ... Southeastern Pennsylvania (" Ben Franklin "); Independence ... Cross; and Safeguard Scientifics ("Safeguard") (NYSE: SFE ... funding initiative over a four year period to grow ... burgeoning economic vitality in digital health, Ben Franklin ...
Breaking Biology Technology:
(Date:11/29/2016)... -- Nearly one billion matches per second with DERMALOG,s high-speed ... ... DERMALOG is Germany's largest Multi-Biometric supplier: ... (PRNewsFoto/DERMALOG Identification Systems) ... is Germany's largest Multi-Biometric supplier: The company's Fingerprint Identification System is part ...
(Date:11/22/2016)... India , November 22, 2016 According to ... (Fingerprint, IRIS, Palm Print, Face, Vein, Signature, Voice), Multi-Factor), Component (Hardware and ... 2022", published by MarketsandMarkets, the market is expected to grow from USD ... a CAGR of 16.79% between 2016 and 2022. ... ...
(Date:11/19/2016)... Securus Technologies, a leading provider of civil and criminal ... monitoring, announced today that it has offered a challenge ... technology judge determine who has the largest and best ... platform, and the best customer service. "ICSolutions ... we do – which clearly is not the case ...
Breaking Biology News(10 mins):